Levofloxacin Aspire Pharma (Levofloxacin)

Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By blocking these targets, the drug halts bacterial cell division, leading to rapid bactericidal activity and clearance of the infection from the ocular surface.

The dosing regimen for Levofloxacin Aspire Pharma is determined by the prescribing clinician based on the severity of the infection, patient age, and response to therapy. Healthcare professionals set the frequency and duration of eye‑drop administration.

Safety data for ocular levofloxacin during pregnancy and lactation are limited. Clinicians should evaluate the potential benefits against any possible risks before prescribing to pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Levofloxacin offers a broad spectrum of activity against both Gram‑negative and Gram‑positive ocular pathogens and has a low propensity for resistance compared with older agents such as ciprofloxacin. It is often preferred for its once‑ or twice‑daily dosing convenience and strong bactericidal effect.

Store the ophthalmic solution at room temperature, preferably below 25 °C, in its original container. Protect it from moisture, direct sunlight, and extreme temperatures to maintain stability and potency.

The product is applied as eye drops directly onto the affected eye(s) using the supplied dropper. Patients should follow the prescriber's instructions regarding the number of drops per dose and the interval between applications.

Serious adverse events can include corneal ulceration or perforation, severe allergic reactions such as anaphylaxis, and systemic effects like tendon rupture or central nervous system disturbances if systemic absorption occurs. Prompt medical attention is required if these symptoms develop.

Individuals with a known hypersensitivity to levofloxacin, other fluoroquinolones, or any component of the formulation should avoid this product. Caution is also advised for patients with a history of tendon disorders, uncontrolled epilepsy, or those taking interacting medications as outlined in the prescribing information.